Averna Therapeutics
Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA
Company Overview
Snapshot
Founded in January 2022, Averna Therapeutics operates with 51–200 employees. The company has raised $82 million across one funding round from 10 investors, with Delos Capital and Novartis Venture Fund as lead investors. In June 2024, the company launched with its Series A financing to develop redosable genomic medicines.
Business overview
Averna Therapeutics is a biotechnology company focused on developing genomic medicines for a range of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's core technology involves inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome to ensure stable gene integration without disrupting cellular functions. By encoding medicines in RNA, Averna utilizes validated, non-viral delivery platforms designed for safety, efficiency, scalability, and cost-effectiveness, aiming for curative outcomes through redosing. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2025, Averna Therapeutics, led by former. This news highlights the company's strategic focus on a high-need area within genomic medicine and signals strong leadership validation, potentially accelerating its development and market penetration in the specialized therapeutics landscape.
Company Intelligence Q&A
- What was a significant funding event for Averna Therapeutics?
- In June 2024, Averna Therapeutics launched with an $82 million Series A financing round. The round was led by Delos Capital and Novartis Venture Fund.
- What is Averna Therapeutics' primary focus in genomic medicine?
- Averna Therapeutics specializes in developing genomic medicines by inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome, aiming to treat genetic disorders, cancer, and autoimmune conditions.
- What is the company's approach to drug delivery?
- Averna Therapeutics encodes its medicines in RNA and utilizes validated, non-viral delivery platforms designed for safety, efficiency, scalability, and cost-effectiveness, with the intent to allow redosing for curative outcomes.
- When was Averna Therapeutics founded?
- Averna Therapeutics was founded in January 2022.
- What was a recent news highlight for Averna Therapeutics?
- In January 2025, Averna Therapeutics was featured in an article discussing its focus on targeting rare genetic diseases through gene editing, led by former.